MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

Phase 2
Recruiting
Conditions
Acute Stroke
Statin
Dual Antiplatelet Therapy
Interventions
First Posted Date
2021-04-01
Last Posted Date
2024-08-21
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
424
Registration Number
NCT04824911
Locations
🇨🇳

Yenchu Huang, Chiayi City, Taiwan

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

Early Phase 1
Recruiting
Conditions
Platelet Activation Testing Before/After Anti-platelet Therapy
Healthy
Interventions
First Posted Date
2021-03-30
Last Posted Date
2022-04-01
Lead Sponsor
Beth Israel Deaconess Medical Center
Target Recruit Count
125
Registration Number
NCT04822363
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19

Phase 3
Conditions
COVID-19
Thrombosis Pulmonary
Interventions
First Posted Date
2021-03-22
Last Posted Date
2021-03-22
Lead Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Target Recruit Count
204
Registration Number
NCT04808895
Locations
🇮🇹

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Phase 1
Conditions
Acute Ischemic Stroke
Interventions
First Posted Date
2021-03-22
Last Posted Date
2021-03-22
Lead Sponsor
Lumosa Therapeutics Co., Ltd.
Target Recruit Count
64
Registration Number
NCT04809818
Locations
🇺🇸

Lumosa Phase 1 Unit, Cypress, California, United States

The Impact of Air Travel on Passenger Cognitive Functions

Phase 2
Conditions
Air Travel
Interventions
Drug: Melatonin 5 mg
Drug: Citicoline
Drug: Cytochrome C6
Drug: Sodium Chloride Oral Product
Drug: Potassium Chloride Oral Product
Drug: Sodium Citrate Oral Product
Drug: Dextrose Oral Tablet, Chewable
Drug: Domperidone Oral Product
Drug: Simethicone
Drug: Acetylsalicylic acid
Drug: Magnesium hydroxide
Drug: Probiotic Formula
First Posted Date
2021-03-17
Last Posted Date
2021-03-17
Lead Sponsor
Dinara Zhumanbayeva
Target Recruit Count
50
Registration Number
NCT04802785

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Phase 4
Recruiting
Conditions
Anticoagulants
Atrial Fibrillation
Atrial Appendage
Platelet Aggregation Inhibitors
Stroke
Interventions
Drug: Double antiplatelet therapy
Drug: Aspirin
Device: Brain MRI
Other: Neurological tests
First Posted Date
2021-03-15
Last Posted Date
2022-10-17
Lead Sponsor
University Hospital, Bordeaux
Target Recruit Count
60
Registration Number
NCT04796714
Locations
🇫🇷

Bordeaux University Hospital, Pessac, France

🇫🇷

Toulouse University Hospital, Toulouse, France

Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet

Phase 1
Conditions
Cardiovascular Diseases
Interventions
First Posted Date
2021-03-11
Last Posted Date
2021-03-11
Lead Sponsor
Vita Green Health Products Co. Ltd
Target Recruit Count
24
Registration Number
NCT04792723

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Phase 3
Recruiting
Conditions
Cardiac Allograft Vasculopathy
Heart Transplant
Interventions
First Posted Date
2021-02-25
Last Posted Date
2024-07-16
Lead Sponsor
Ottawa Heart Institute Research Corporation
Target Recruit Count
135
Registration Number
NCT04770012
Locations
🇨🇦

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

🇨🇦

Toronto General Hospital UHN, Toronto, Ontario, Canada

🇨🇦

St.Pauls Hospital, Vancouver, British Columbia, Canada

Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI

Phase 3
Conditions
ST Elevation Myocardial Infarction
Interventions
First Posted Date
2021-02-15
Last Posted Date
2021-02-15
Lead Sponsor
Assiut University
Target Recruit Count
160
Registration Number
NCT04754789

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

Phase 3
Recruiting
Conditions
NSTEMI
Unstable Angina
STEMI
Interventions
First Posted Date
2021-01-22
Last Posted Date
2023-04-21
Lead Sponsor
Collegium Medicum w Bydgoszczy
Target Recruit Count
4500
Registration Number
NCT04718025
Locations
🇵🇱

Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland

© Copyright 2025. All Rights Reserved by MedPath